Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed So...(rfilzomib. In addition to this Phase 1b/...),Health

Date:10/10/2007

rfilzomib. In addition to this Phase 1b/2 trial in solid tumors, carfilzomib is currently being evaluated in two Phase 2 single-agent trials in myeloma, a Phase 1 study in lymphoma, and will enter clinical testing in combination with an FDA-approved agent in myeloma by the end of the year.

About South Texas Accelerated Research Therapeutics (START)

South Texas Accelerated Research Therapeutics is dedicated to the conduct of Phase 1 Clinical Trials of novel anticancer agents. The mission of START is to accelerate the development of new anti-cancer drugs with the purpose of improving quality of life and survival for patients with cancer. START consists of a team of highly trained physicians and staff, with extensive experience in Phase 1 clinical trials research. Research physicians at START have set unprecedented standards for the development of anticancer agents, having played a key role in the clinical development of numerous cancer drugs that are now approved by the Food and Drug Administration. Through the work of these physicians and their highly trained staff, advances have led to improved understanding and treatment of cancer. START is headquartered in San Antonio, Texas. For more information, please visit http://www.startthecure.com.

About Proteolix

Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in different types of cancer, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic pote
'/>"/>

SOURCE Proteolix, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. Protox Announces Positive Clinical Data from Prostate Cancer Study